GRF 6019

Drug Profile

GRF 6019

Alternative Names: GRF6019; Plasma-based therapeutic; Plasma-based therapeutic - Alkahest/Grifols

Latest Information Update: 02 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkahest; Grifols
  • Developer Alkahest; Grifols; Stanford University School of Medicine
  • Class Antidementias; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Clinical Phase Unknown Neurodegenerative disorders

Most Recent Events

  • 25 Apr 2018 Phase-II clinical trials in Alzheimer's disease in Unknown location (IV)
  • 12 Feb 2018 Clinical trials in Neurodegenerative disorders in Spain, USA before February 2018
  • 01 Nov 2017 Efficacy and adverse events data from a clinical trial in Alzheimer's disease released by Alkahest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top